Case Report

doi: http://dx.doi.org/10.4314/ovj.v11i1.2

Introduction

Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs (Zandvliet, 2016). Classification of lymphoma in dogs is based on anatomic location, and the most common anatomic form of lymphoma is the multicentric form that affects the peripheral lymph nodes. Lymphoma is the most commonly managed neoplasia in veterinary medicine, and several chemotherapeutic protocols have been developed (Zandvliet, 2016). In veterinary medicine, anthracyclines, such as doxorubicin and epirubicin, are commonly administered for a variety of malignancies, including lymphoma (Elliott et al., 2013; Curran and Thamm, 2016; Wang et al., 2016). Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective, and the increased risk of cardiotoxicity in patients using doxorubicin is very well known (Mauldin et al., 1992). However, there is not enough evidence for the development of cardiac toxicity using several anthracyclines as chemotherapeutic agents.

Case Description

An 8-year-old, castrated, mixed-breed dog was diagnosed with multicentric lymphoma and received multi-agent chemotherapy. Complete remission was achieved, but the patient had a relapse of lymphoma. After third-line chemotherapy with epirubicin, the patient was diagnosed with dilated cardiomyopathy. The total cumulative doses of doxorubicin, mitoxantrone, and epirubicin were 125, 8, and 125 mg/m², respectively. Although the patient was treated with cardiac drugs and clinically stabilized, the patient had a relapse of lymphoma and died shortly after the diagnosis of cardiomyopathy.

Conclusion

The patient was suspected to have anthracycline-induced cardiomyopathy. Further studies are required to establish prevention and management strategies for dogs receiving potentially cardiotoxic therapies, such as anthracyclines.

Keywords: AICM, Anthracycline-induced cardiomyopathy, Dog, Lymphoma.

Cardiomyopathy in a dog with multicentric lymphoma following treatment with several anthracyclines

Michihito Tagawa1*, Genya Shimbo2, Akiko Uemura1 and Kotaro Matsumoto1

1Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan
2Veterinary Teaching Hospital, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan
3Department of Clinical Veterinary Science, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan

Abstract

Background: Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs. Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective; however, there is not enough evidence for the development of cardiac toxicity using several anthracyclines as chemotherapeutic agents.

Case Description: An 8-year-old, castrated, mixed-breed dog was diagnosed with multicentric lymphoma and received multi-agent chemotherapy. Complete remission was achieved, but the patient had a relapse of lymphoma. After third-line chemotherapy with epirubicin, the patient was diagnosed with dilated cardiomyopathy. The total cumulative doses of doxorubicin, mitoxantrone, and epirubicin were 125, 8, and 125 mg/m², respectively. Although the patient was treated with cardiac drugs and clinically stabilized, the patient had a relapse of lymphoma and died shortly after the diagnosis of cardiomyopathy.

Conclusion: The patient was suspected to have anthracycline-induced cardiomyopathy. Further studies are required to establish prevention and management strategies for dogs receiving potentially cardiotoxic therapies, such as anthracyclines.

Keywords: AICM, Anthracycline-induced cardiomyopathy, Dog, Lymphoma.
systolic left ventricular wall thicknesses were 8.6 and 14.2 mm, respectively. A mitoxantrone dose of 4 mg/m² was administered twice. The dog achieved a second complete remission, but relapsed again 6 months after second-line chemotherapy. Subsequently, the dog received third-line chemotherapy, including epirubicin (25 mg/m², IV) and vincristine, resulting in high cytoidal effects. One week after five cycles of epirubicin (cumulative epirubicin dose, 125 mg/m²), the dog was admitted to the hospital with a history of orthopnea, swelling of legs, and fatigue. On physical examination, muffled heart sounds were identified. Thoracic radiographs revealed generalized cardiomegaly (Fig. 3), and vertebral heart size was 11.5 (normal range, 9.7 ± 0.5 vertebrae). Electrocardiography (ECG) showed accelerated idioventricular rhythm with a wide QRS complex (Fig. 4). Echocardiography revealed severe diffuse hypokinesia with an LVEF of 46.4% and LVFS of 18.8% (Fig. 2b), and reduced diastolic and systolic left ventricular wall thickness (7.0 and 8.6 mm, respectively). Troponin I was 1.185 ng/ml (FUJIFILM VET Systems, Tokyo, reference range; 0.006–0.129 ng/ml). Based on these findings, a diagnosis of anthracycline-induced cardiomyopathy (AICM) was established. The dog was treated with
benazepril (0.32 mg/kg, PO, q24h) and pimobendane (0.16 mg/kg, PO, q12h). Seven days after the treatment for cardiomyopathy, the dog was clinically stable, and echocardiography revealed improved cardiac function with LVEF of 66.2% and LVFS of 30.4%. However, after 9 days, the condition worsened, and a large number of lymphoblast cells were observed in the peripheral blood smear of the dog. Cytosine arabinoside (300 mg/m², IV, drip infusion for 3 hours) was administered, but the dog subsequently died 22 days after the diagnosis of cardiomyopathy. Necropsy was not performed.

**Discussion**

Anthracyclines, such as doxorubicin and epirubicin, are highly effective and frequently used antineoplastic drugs prescribed for a variety of malignancies, especially lymphoma (Elliott et al., 2013; Curran and Thamm, 2016). However, these drugs may have side effects such as myelotoxicity, nausea, vomiting, alopecia, and tissue necrosis in cases of extravasation, and the most serious chronic effects of anthracyclines are dose-dependent and irreversible cardiotoxicity. The mechanisms associated with anthracycline-induced cardiotoxicity involve inflammation, oxidative stress, apoptosis, mitochondrial impairment, and dysregulation of autophagy, which have not been fully understood (Prathumsap et al., 2020). Anthracycline-induced cardiotoxicity is characterized by cardiomyopathy, ventricular dysfunction, pericarditis-myocarditis syndrome, or arrhythmias. Regarding doxorubicin, chronic cardiotoxicity is most commonly seen with doses that exceed 180 mg/m² or more than six doses in dogs, but cardiotoxicity can occur with any cumulative dose (Mauldin et al., 1992; Willcox et al., 2020).

Epirubicin, a stereoisomer of doxorubicin, has been reported to be less cardiotoxic than doxorubicin without compromising anti-tumor efficacy (Smith et al., 2010). Relative to doxorubicin, the equivalence ratio for epirubicin was 0.7 (McGowan et al., 2017). It is now being used instead of doxorubicin to reduce cardiotoxicity; however, the toxicity of epirubicin has not been fully evaluated in veterinary medicine, and the absolute maximum cumulative dose of epirubicin in dogs has not been defined (Kim et al., 2007; Marrington et al., 2012; Elliott et al., 2013). It has been reported that AICM occurs in dogs receiving epirubicin and doxorubicin (Lee et al., 2015). The report suggested that previous anthracycline therapy could increase the risk of cardiotoxicity. In this report, the dog was treated with cumulative epirubicin doses of 125 mg/m², with previously administered six cycles of doxorubicin. Mitoxantrone, a synthetic anthracenedione, was developed as a doxorubicin analogue in a program to find a cytotoxic agent with decreased cardiotoxicity compared with doxorubicin (Alderton et al., 1992). In fact, past studies using dog models revealed that mitoxantrone was less cardiotoxic than doxorubicin, and mitoxantrone did not show cardiotoxicity in dogs that were pretreated with a threshold cardiotoxic dose of doxorubicin (Henderson et al., 1982; Sparano et al., 1982; Tham et al., 1987). However, a recent large human cohort study reported that mitoxantrone is cardiotoxic.
and four to five times more toxic than doxorubicin (Feijen et al., 2019). Further studies are required to clarify the additive or synergistic interactions of anthracyclines and other cardiotoxic drugs in dogs. In human medicine, therapeutic strategies for anthracycline-induced heart failure are not well studied. Angiotensin converting enzyme inhibitor (ACEI), diuretics, and β-blockers are used, but once symptomatic, anthracycline-induced cardiotoxicity is associated with markedly decreased survival (Cai et al., 2019). In addition, a recent study showed that administration of ACEI or a combination of beta-blockers at the early detection of anthracycline-induced cardiac insufficiency restored LVEF and reduced cardiac events (Mehta et al., 2018). However, poor tolerance to beta-blockade initiation in a human AICM patient has been reported (Tabet et al., 2006). In this study, the dog was treated with ACEI and a positive inotropic agent, following which the dog became clinically stable and echocardiographic improvement was observed. However, it was difficult to evaluate the efficacy of these drugs because the patient had a relapse of lymphoma and died shortly after the diagnosis of cardiomyopathy. There are four main strategies to protect against cardiotoxicity induced by anthracyclines: decreasing lifetime cumulative dose, prolonged intravenous infusion, liposomal formulation, and the addition of dexrazoxane (Graffagnino et al., 2020). Liposomal encapsulated doxorubicin and dexrazoxane administration has been reported in a few veterinary studies, but the long-term cardioprotective effects of these strategies have not been evaluated (FitzPatrick et al., 2010; Teske et al., 2011). Furthermore, these strategies are not widely used in veterinary medicine because of the short life span of dogs and the high costs incurred. In humans, LVEF is a recommended method used to evaluate the systolic function in patients treated with anthracycline drugs (Cai et al., 2019). Cancer therapeutics-related cardiac dysfunction is defined as a decrease in the LVEF by >10% points to a value below the lower limit of normal (usually LVEF ≥50%) (Zamorano et al., 2016). However, although LVFS is a recommended method for evaluating dogs receiving doxorubicin (Surachetpong et al., 2016), the diagnostic criteria for AICM of dogs have not been described, and the usefulness of LVFS in monitoring dogs treated with doxorubicin has not been evaluated well. In this case report, the diagnosis of AICM was based on echocardiography, ECG findings, and heart failure symptoms. Cardiac biomarkers, such as troponin, can be good indicators of doxorubicin-induced myocardial injury and can provide useful diagnostic information, especially when used in combination with echocardiography assessment (Octavia et al., 2012). In veterinary medicine, it was reported that dogs treated with doxorubicin had increased troponin levels, which were detected before echocardiographic value changes (Surachetpong et al., 2016). Furthermore, ECG abnormalities could occur after dogs received a low doxorubicin dosage (Mauldin et al., 1992). It is necessary to establish a monitoring strategy for the early detection of cardiotoxic effects in dogs if the maximum cumulative dose of doxorubicin is achieved or several cardiotoxic agents are used.

In this case report, we described suspected AICM in a dog receiving several cardiotoxic drugs, including doxorubicin, epirubicin, and mitoxantrone. The additive or synergistic effect of these cardiotoxic drugs in dogs is poorly documented. Further studies are required to establish prevention and management strategies for dogs receiving potentially cardiotoxic therapies such as anthracyclines.

Conflict of interest

The authors declare that there is no conflict of interest.

References


